Strain difference of oxidative metabolism of the sedative-hypnotic zaleplon by aldehyde oxidase and cytochrome P450 in vivo and in vitro in rats. 2013

Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
Division of Medicinal Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan.

The in vivo and in vitro metabolism of the sedative-hypnotic agent zaleplon (ZAL) to 5-hydroxylated ZAL (5-oxo-ZAL) and N-desethylated ZAL (desethyl-ZAL) was studied in four strains of rats. Incubation of ZAL with liver microsomes afforded desethyl-ZAL via cytochrome P450-catalyzed reaction, with little strain difference. In contrast, incubation of ZAL with liver cytosol afforded 5-oxo-ZAL with marked strain differences. ZAL hydroxylase activity was well correlated with aldehyde oxidase activity in these strains. The highest level of 5-oxo-ZAL and the highest activity of aldehyde oxidase were observed in cytosol from Sea:SD rats, followed by Jcl:SD rats, while Crj:SD and WKA/Sea rats showed low levels. When ZAL was administered to Sea:SD and WKA/Sea rats, both 5-oxo-ZAL and desethyl-ZAL were detected in blood as the major in vivo metabolites. However, the concentration of 5-oxo-ZAL was far higher in Sea:SD rats than in WKA/Sea rats, while that of desethyl-ZAL was far lower in Sea:SD rats. The levels of 5-oxo-ZAL in blood were closely correlated with the strain differences of cytosolic ZAL hydroxylase activity and benzaldehyde oxidase activity. Our results indicate that variability in the formation of 5-oxo-ZAL from ZAL in vivo in various strains of rats is primarily due to strain differences of hepatic aldehyde oxidase activity.

UI MeSH Term Description Entries
D008297 Male Males
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D042931 Aldehyde Oxidase An aldehyde oxidoreductase expressed predominantly in the LIVER; LUNGS; and KIDNEY. It catalyzes the oxidation of a variety of organic aldehydes and N-heterocyclic compounds to CARBOXYLIC ACIDS, and also oxidizes quinoline and pyridine derivatives. The enzyme utilizes molybdenum cofactor and FAD as cofactors. Oxidase, Aldehyde
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
March 1999, Drug metabolism and disposition: the biological fate of chemicals,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
March 2004, Journal of pharmacological sciences,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
April 1998, Xenobiotica; the fate of foreign compounds in biological systems,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
October 2002, Xenobiotica; the fate of foreign compounds in biological systems,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
December 2006, Drug metabolism and pharmacokinetics,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
August 2016, Drug metabolism and disposition: the biological fate of chemicals,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
November 2000, Clinical therapeutics,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
October 1982, Journal of medicinal chemistry,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
January 2002, European journal of pharmacology,
Chiaki Tanoue, and Kazumi Sugihara, and Naoto Uramaru, and Yoko Watanabe, and Yoshitaka Tayama, and Shigeru Ohta, and Shigeyuki Kitamura
January 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Copied contents to your clipboard!